Abstract

Highlights

*

CD40 expression correlates with the type I anti-tumor response and better survival.

*

Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RASmut melanoma compared to nevi.

*

RAS mutation correlates with reduced CD40 expression in malignant melanoma.

*

CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma.

Details

Title
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
Author
Yan, Chi; Richmond, Ann
Pages
1-5
Section
Letter to the Editor
Publication year
2021
Publication date
2021
Publisher
BioMed Central
e-ISSN
14764598
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s12943-021-01442-3
ProQuest document ID
2599227531
Copyright
© 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.